NP_005148.2
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
122,873 Da
NCBI Official Full Name
tyrosine-protein kinase ABL1 isoform a
NCBI Official Synonym Full Names
c-abl oncogene 1, non-receptor tyrosine kinase
NCBI Official Synonym Symbols
ABL; JTK7; p150; c-ABL; v-abl; bcr/abl [Similar Products]
NCBI Protein Information
tyrosine-protein kinase ABL1; proto-oncogene c-Abl; bcr/c-abl oncogene protein; Abelson tyrosine-protein kinase 1; c-abl oncogene 1, receptor tyrosine kinase; proto-oncogene tyrosine-protein kinase ABL1; v-abl Abelson murine leukemia viral oncogene homolog 1
UniProt Protein Name
Tyrosine-protein kinase ABL1
UniProt Synonym Protein Names
Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; Proto-oncogene c-Abl; p150
UniProt Synonym Gene Names
UniProt Entry Name
ABL1_HUMAN
NCBI Summary for Abl
The ABL1 protooncogene encodes a cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of c-Abl protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. The t(9;22) translocation results in the head-to-tail fusion of the BCR (MIM:151410) and ABL1 genes present in many cases of chronic myelogeneous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for ABL1. The ABL1 gene is expressed as either a 6- or 7-kb mRNA transcript, with alternatively spliced first exons spliced to the common exons 2-11. [provided by RefSeq, Jul 2008]
UniProt Comments for Abl
Abl: an ubiquitously expressed and highly conserved proto-oncogenic tyrosine kinase. c-Abl protein is distributed in both the nucleus and the cytoplasm of cells. Negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. It has been implicated in regulation of cell proliferation, differentiation, apoptosis, cell adhesion and stress response. The Philadephia chromosome translocation t(9;22)(q34;q11) creates a Bcr-Abl fusion protein, responsible for 90% of chronic myelogenous leukemia (CML) and ~25% of acute lymphoblastic leukemia (ALL). Inhibitors: Gleevec (imatinib, Glivec), Dasatinib. Two alternatively-spliced isoforms have been described.
Protein type: Kinase, protein; Protein kinase, TK; Protein kinase, tyrosine (non-receptor); EC 2.7.10.2; Oncoprotein; TK group; Abl family
Chromosomal Location of Human Ortholog: 9q34.1
Cellular Component: nucleoplasm; extrinsic to internal side of plasma membrane; nuclear membrane; mitochondrion; perinuclear region of cytoplasm; leading edge; cytoplasm; nucleolus; cytosol; nucleus; actin cytoskeleton
Molecular Function: protein C-terminus binding; actin monomer binding; non-membrane spanning protein tyrosine kinase activity; magnesium ion binding; protein kinase activity; actin filament binding; protein binding; syntaxin binding; DNA binding; manganese ion binding; protein-tyrosine kinase activity; mitogen-activated protein kinase binding; nicotinate-nucleotide adenylyltransferase activity; SH3 domain binding; ATP binding; receptor binding
Biological Process: DNA damage induced protein phosphorylation; positive regulation of apoptosis; cerebellum morphogenesis; negative regulation of BMP signaling pathway; B cell receptor signaling pathway; transitional one stage B cell differentiation; elevation of cytosolic calcium ion concentration; regulation of endocytosis; negative regulation of mitotic cell cycle; cell cycle arrest; neuromuscular process controlling balance; positive regulation of oxidoreductase activity; spleen development; mitosis; positive regulation of I-kappaB kinase/NF-kappaB cascade; negative regulation of I-kappaB kinase/NF-kappaB cascade; positive regulation of peptidyl-tyrosine phosphorylation; muscle cell differentiation; DNA damage response, signal transduction resulting in induction of apoptosis; positive regulation of osteoblast proliferation; negative regulation of ubiquitin-protein ligase activity; autophagy; response to oxidative stress; actin cytoskeleton organization and biogenesis; axon guidance; peptidyl-tyrosine phosphorylation; alpha-beta T cell differentiation; platelet-derived growth factor receptor signaling pathway; mitochondrial depolarization; positive regulation of mitotic cell cycle; Bergmann glial cell differentiation; regulation of transcription, DNA-dependent; collateral sprouting; cell differentiation; B cell proliferation during immune response; regulation of cell adhesion; epidermal growth factor receptor signaling pathway; cell migration; mismatch repair; thymus development; activated T cell proliferation; DNA damage response, signal transduction; B-1 B cell homeostasis; protein modification process; regulation of cell proliferation; microspike biogenesis; innate immune response; positive regulation of muscle cell differentiation; regulation of autophagy; positive regulation of release of sequestered calcium ion into cytosol; negative regulation of cell-cell adhesion; blood coagulation; response to DNA damage stimulus
Disease: Leukemia, Chronic Myeloid
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-Abl antibody
Pathways associated with anti-Abl antibody
Diseases associated with anti-Abl antibody
Disease Name |
Pubmed Publications |
Neoplasms Antibodies |
>518 publications with Abl and Neoplasms |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Antibodies |
>276 publications with Abl and Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
Precursor Cell Lymphoblastic Leukemia-Lymphoma Antibodies |
>115 publications with Abl and Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Cell Transformation, Neoplastic Antibodies |
>51 publications with Abl and Cell Transformation, Neoplastic |
Anemia Antibodies |
>18 publications with Abl and Anemia |
Drug Toxicity Antibodies |
>16 publications with Abl and Drug Toxicity |
Neoplasms, Experimental Antibodies |
>12 publications with Abl and Neoplasms, Experimental |
Disease Models, Animal Antibodies |
>9 publications with Abl and Disease Models, Animal |
Cardiovascular Diseases Antibodies |
>9 publications with Abl and Cardiovascular Diseases |
Nervous System Diseases Antibodies |
>6 publications with Abl and Nervous System Diseases |
Organs/Tissues associated with anti-Abl antibody
|